Selegilin exerts antidepressant-like effects during the forced swim test in adrenocorticotropic hormone-treated rats

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 639-644

  Kitamura, Yoshihisa ^a   Kitagawa, Kouhei ^a,b   Kimoto, Shizue ^b   Sagara, Hidenori ^b   Shibata, Kazuhiko ^b   Kawasaki, Hiromu ^a   Sendo, Toshiaki ^b   Gomita, Yutaka ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Dopamine D3 receptor; Forced swim test; Monoamine oxidase B; Selegiline; Treatment resistance depression

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIDEPRESSANT AGENT; CORTICOTROPIN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MONOAMINE OXIDASE B INHIBITOR; NAFADOTRIDE; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; HORMONAL THERAPY; IMMOBILIZATION; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

EID: 42349107737     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0072150     Document Type: Article

References (25)

1. Carpenter WT, Bunney WE. Adrenal cortical activity in depressive illness. Am J Psychiatry. 1971;128:31-40.
2. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. Arch Gen Psychiatry. 1976;33:1039-1044.
3. Kitamura Y, Araki H, Gomita Y. Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol Biochem Behav. 2002;71:63-69.
4. Porsolt RD, Anton G, Blavet N. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379-391.
5. De Montigny C, Gruberg F, Mayer A. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry. 1981;138:252-256.
6. Sanderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607-615.
7. Higuchi H, Kamata M, Sugawara Y, Yoshida K. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. Clin Neuropharmacol. 2005;28:191-192.
8. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Ravan Press Ltd.; 1995. p. 921-931.
9. Simazu S, Minami A, Kusumoto H, Yoneda F. Antidepressant-like effects of selegiline in the forced swim test. Eur J Neuropsychopharmacol. 2005;15:563-571.
10. Li B, Suemaru K, Cui R, Kitamura Y, Gomita Y, Araki H. Repeated electroconvulsive stimuli increase brain-derived neurotrophic factor in ACTH-treated rats. Eur J Pharmacol. 2006;529:114-121.
11. Fink M. How does convulsive therapy work? Neuropsychopharmacology. 1990;3:73-82.
12. Willner P. Animal models as simulation of depression. Trends Pharmacol Sci. 1991;12:131-136.
13. Ainsworth K, Smith SE, Zetterstrom TSC. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology. 1998;140:470-477.
14. Ichikawa J, Melzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol. 1995;281:255-261.
15. Tanda G, Carboni E, Frau R, Chiara DG. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology. 1994;115:285-288.
16. Spyraki C, Fibiger HC. Behavioural evidence for supersensitivity of postsynapyic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol. 1981;74:195-206.
17. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Chronic desipramine enhances amphetamine-induced increase in interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol. 1991;195:63-73.
18. Rossetti ZL, D'Aquila PS, Hmaidan Y, Gessa GL, Serra G. Repeated treatment with imipramine potenciates cocaine-induced dopamine release and motor stimulation. Eur J Pharmacol. 1991;201:243-245.
19. Yeghiayan SK, Anderson SL, Baldessarini RJ. Lack of effect of chronic clorgyline or selegiline on dopamine and serotonin transporters in rat caudate-putamen or nucleus accumbens septi. Neurosci Lett. 1997;236:147-150.
20. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 94:469-492.
21. D'Aquila PS, Collu M, Pani L, Gessa GL, Serra G. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur J Pharmacol. 1994;262:107-111.
22. Levant B, Vansell NR. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology. 1997;17:67-71.
23. 3 receptors in the rat brain. Eur J Pharmacol. 1998;351:31-37.
24. Lammer CH, Diaz J, Schwartz JC, Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiat. 2000;5:378-388.
25. Rogoz Z, Skuza G, Klodzinska A. Anxiolytic and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats. Pol J Pharmacol. 2004;56:519-526.